Compugen Ltd CGEN
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $72.76M, +161.1% YoY · Filed Mar 2, 2026
Compugen Ltd (CGEN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $72.8 million and net income of $35.3 million. Free cash flow was $31.3 million. As of Dec 31, 2025 it held $99.9 million in cash and investments and $3.0 million in total debt.
Revenue
$72.76M
+161.1% vs prior year
Net income
$35.34M
+348.4% vs prior year
Operating cash flow
$31.63M
-36.2% vs prior year
Free cash flow
$31.33M
-36.7% vs prior year
EPS
$0.38
+337.5% vs prior year
Dividend per share
None
Shares outstanding
94.55M
+5.6% vs prior year
Net cash
$96.92M
FY 2025
Operating margin
43.1%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Holon, Israel
- SEC filer status
- Accelerated filer
- SEC CIK
- 1119774
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M | $6.0M |
| Operating income | $31.3M | -$14.9M | -$13.0M | -$35.4M | -$35.1M |
| Net income | $35.3M | -$14.2M | -$18.8M | -$33.7M | -$34.2M |
| Diluted EPS | $0.38 | -$0.16 | -$0.21 | -$0.39 | -$0.41 |
| Operating cash flow | $31.6M | $49.6M | -$35.9M | -$34.1M | -$22.7M |
| Free cash flow | $31.3M | $49.5M | -$36.1M | -$34.6M | -$23.0M |
| Total assets | $156.6M | $115.0M | $121.3M | $94.2M | $132.2M |
| Stockholders' equity | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M |
| Cash and investments | $99.9M | $41.9M | $25.6M | $11.1M | $7.8M |
| Total debt | $3.0M | $2.9M | $1.4M | $1.9M | $2.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Aug 3, 2026 | Aug 3, 2026 |
| 6-K | Current report (foreign issuer) | Aug 3, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | May 18, 2026 | May 18, 2026 |
| 20-F | Annual report (foreign issuer) | Mar 2, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 2, 2026 | Mar 2, 2026 |
All 607 Compugen Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.